Table 2 Summary of best overall patient response
From: Phase II trial of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
Response | N = 80 (%) | 95% CI |
|---|---|---|
Complete response | 0 (0) | |
Partial response | 26 (32.5) | |
Stable disease | 27 (33.8) | |
Progressive disease | 27 (33.8) | |
ORR% | 33.8 | 21.3–43.8 |
CBR% | 66.2 | 56.3–75.0 |